Literature DB >> 17198477

Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction.

J A Solís Herruzo1, I García Ruiz, M Pérez Carreras, M T Muñoz Yagüe.   

Abstract

Non-alcoholic fatty liver disease represents a set of liver lesions similar to those induced by alcohol that develop in individuals with no alcohol abuse. When lesions consist of fatty and hydropic degeneration, inflammation, and eventually fibrosis, the condition is designated non-alcoholic steatohepatitis (NASH). The pathogenesis of these lesions is not clearly understood, but they are associated with insulin resistance in most cases. As a result, abdominal fat tissue lipolysis and excessive fatty acid uptake by the liver occur. This, together with a disturbance of triglyceride export as VLDL, results in fatty liver development. Both the inflammatory and hepatocellular degenerative components of NASH are attributed to oxidative stress. Mitochondrial respiratory chain loss of activity plays a critical role in the genesis of latter stress. This may be initiated by an increase in the hepatic TNFalpha, iNOS induction, peroxynitrite formation, tyrosine nitration and inactivation of enzymes making up this chain. Consequences of oxidative stress include: lipid peroxidation in cell membranes, stellate cell activation in the liver, liver fibrosis, chronic inflammation, and apoptosis.

Entities:  

Mesh:

Year:  2006        PMID: 17198477     DOI: 10.4321/s1130-01082006001100006

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  13 in total

Review 1.  Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.

Authors:  Jordi Camps; Jorge Joven
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

2.  An experimental research on chronic intermittent hypoxia leading to liver injury.

Authors:  Shu-zhi Feng; Jian-li Tian; Qiang Zhang; Hui Wang; Ning Sun; Yun Zhang; Bao-yuan Chen
Journal:  Sleep Breath       Date:  2010-06-27       Impact factor: 2.816

Review 3.  Inflammatory mediators of hepatic steatosis.

Authors:  Elizabeth Hijona; Lander Hijona; Juan I Arenas; Luis Bujanda
Journal:  Mediators Inflamm       Date:  2010-03-16       Impact factor: 4.711

4.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

5.  Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.

Authors:  Lascelles E Lyn-Cook; Margot Lawton; Ming Tong; Elizabeth Silbermann; Lisa Longato; Ping Jiao; Princess Mark; Jack R Wands; Haiyan Xu; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Measurement of serum paraoxonase-1 activity in the evaluation of liver function.

Authors:  Jordi Camps; Judit Marsillach; Jorge Joven
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

7.  Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease.

Authors:  Kate S Collison; Zakia Maqbool; Soad M Saleh; Angela Inglis; Nadine J Makhoul; Razan Bakheet; Mohammed Al-Johi; Rana Al-Rabiah; Marya Z Zaidi; Futwan A Al-Mohanna
Journal:  J Lipid Res       Date:  2008-11-11       Impact factor: 5.922

8.  Effect of α-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes.

Authors:  Yong Zhang; Xia Yang; Hongyang Shi; Lei Dong; Jian Bai
Journal:  Lipids Health Dis       Date:  2011-07-25       Impact factor: 3.876

9.  Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells.

Authors:  Yong Zhang; Rongliang Xue; Zhenni Zhang; Xia Yang; Hongyang Shi
Journal:  Lipids Health Dis       Date:  2012-01-05       Impact factor: 3.876

10.  Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome?

Authors:  Fernando Sánchez-Patán; Raquel Anchuelo; Maria-Angeles Aller; Elena Vara; Cruz García; Maria-Paz Nava; Jaime Arias
Journal:  Lipids Health Dis       Date:  2008-02-13       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.